This article may contain affiliate links that Microsoft and/or the publisher may receive a commission from if you buy a product or service through those links.

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.

Libre Drives Diabetes Care: Abbott’s Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

Omnipod 5 is now available with both Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 Continuous Glucose Monitoring (CGM) sensor compatibility. Indicated for individuals aged two years and older ...

For the full calendar of 2024, Abbott recorded sales ... Based on its FreeStyle Libre system, the Libre Rio is aimed at adults with Type 2 diabetes who are not taking insulin, while the Lingo ...

Omnipod 5 is available with both Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 Continuous Glucose Monitoring (“CGM”) sensor compatibility. The latest development represents a significant ...

Omnipod 5 is available with both Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 Continuous Glucose Monitoring (“CGM”) sensor compatibility. The latest development represents a significant step forward ...

Meanwhile, Abbott's FreeStyle Libre and FreeStyle Libre 2 flash CGM systems remain available to patients and listed on the NHS Drug Tariff. The FreeStyle Libre 3 system consists of the sensor ...

Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.